Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.

Masters MC, Krueger KM, Williams JL, Morrison L, Cohn SE.

Expert Rev Clin Pharmacol. 2019 Dec;12(12):1129-1143. doi: 10.1080/17512433.2019.1698946. Review.

PMID:
31774001
2.

Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation.

Krueger KM, Ison MG, Ghossein C.

Am J Kidney Dis. 2020 Mar;75(3):417-425. doi: 10.1053/j.ajkd.2019.06.014. Epub 2019 Oct 1. Review.

PMID:
31585683
3.

Insomnia as a Precipitating Factor in New Onset Mental Illness: a Systematic Review of Recent Findings.

Pigeon WR, Bishop TM, Krueger KM.

Curr Psychiatry Rep. 2017 Aug;19(8):44. doi: 10.1007/s11920-017-0802-x. Review.

PMID:
28616860
4.

Statin Prescribing Practices in the Comprehensive Care for HIV-Infected Patients.

Kelly SG, Krueger KM, Grant JL, Penugonda S, Feinstein MJ, Taiwo BO, Achenbach CJ.

J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e26-e29. doi: 10.1097/QAI.0000000000001454. No abstract available.

PMID:
28520617
5.

Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.

Esbenshade TA, Browman KE, Miller TR, Krueger KM, Komater-Roderwald V, Zhang M, Fox GB, Rueter L, Robb HM, Radek RJ, Drescher KU, Fey TA, Bitner RS, Marsh K, Polakowski JS, Zhao C, Cowart MD, Hancock AA, Sullivan JP, Brioni JD.

J Pharmacol Exp Ther. 2012 Oct;343(1):233-45. doi: 10.1124/jpet.112.194126. Epub 2012 Jul 19.

PMID:
22815533
6.

Applying analytical ultracentrifugation to nanocrystal suspensions.

Jamison JA, Krueger KM, Mayo JT, Yavuz CT, Redden JJ, Colvin VL.

Nanotechnology. 2009 Sep 2;20(35):355702. doi: 10.1088/0957-4484/20/35/355702. Epub 2009 Aug 12.

PMID:
19671976
7.

Size-dependent sedimentation properties of nanocrystals.

Jamison JA, Krueger KM, Yavuz CT, Mayo JT, LeCrone D, Redden JJ, Colvin VL.

ACS Nano. 2008 Feb;2(2):311-9. doi: 10.1021/nn700144m.

PMID:
19206632
8.

The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.

Zhao C, Sun M, Bennani YL, Gopalakrishnan SM, Witte DG, Miller TR, Krueger KM, Browman KE, Thiffault C, Wetter J, Marsh KC, Hancock AA, Esbenshade TA, Cowart MD.

J Med Chem. 2008 Sep 11;51(17):5423-30. doi: 10.1021/jm8003625. Epub 2008 Aug 7.

PMID:
18683917
9.

A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands.

Miller TR, Baranowski JL, Estvander BR, Witte DG, Carr TL, Manelli AM, Krueger KM, Cowart MD, Brioni JD, Esbenshade TA.

Assay Drug Dev Technol. 2008 Jun;6(3):339-49. doi: 10.1089/adt.2007.118.

PMID:
18593375
10.

Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.

Altenbach RJ, Liu H, Banfor PN, Browman KE, Fox GB, Fryer RM, Komater VA, Krueger KM, Marsh K, Miller TR, Pan JB, Pan L, Sun M, Thiffault C, Wetter J, Zhao C, Zhou D, Esbenshade TA, Hancock AA, Cowart MD.

J Med Chem. 2007 Nov 1;50(22):5439-48. Epub 2007 Oct 6.

PMID:
17918921
11.

An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activity.

Bongers G, Krueger KM, Miller TR, Baranowski JL, Estvander BR, Witte DG, Strakhova MI, van Meer P, Bakker RA, Cowart MD, Hancock AA, Esbenshade TA, Leurs R.

J Pharmacol Exp Ther. 2007 Dec;323(3):888-98. Epub 2007 Sep 12.

PMID:
17855474
12.

A new family of histamine H3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series.

Cowart M, Sun M, Zhao C, Witte DG, Miller TR, Krueger KM, Browman K, Fox GB, Bennani YL, Esbenshade TA, Hancock AA.

Inflamm Res. 2007 Apr;56 Suppl 1:S47-8. No abstract available.

PMID:
17806176
13.

Pharmacological classification of histamine H3 receptor agents across species is attributable to transmembrane 3 sequence differences.

Esbenshade TA, Estvander BR, Miller TR, Baranowski JL, Sharma R, Hancock AA, Krueger KM.

Inflamm Res. 2007 Apr;56 Suppl 1:S45-6. No abstract available.

PMID:
17806175
14.

Shape-controlled synthesis of CdSe tetrapods using cationic surfactant ligands.

Asokan S, Krueger KM, Colvin VL, Wong MS.

Small. 2007 Jul;3(7):1164-9. No abstract available.

PMID:
17465440
15.

Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.

Cowart M, Gfesser GA, Browman KE, Faghih R, Miller TR, Milicic I, Baranowski JL, Krueger KM, Witte DG, Molesky AL, Komater VA, Buckley MJ, Diaz GJ, Gagne GD, Zhou D, Deng X, Pan L, Roberts EM, Diehl MS, Wetter JM, Marsh KC, Fox GB, Brioni JD, Esbenshade TA, Hancock AA.

Biochem Pharmacol. 2007 Apr 15;73(8):1243-55. Epub 2007 Feb 23.

PMID:
17371699
16.

Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.

Witte DG, Yao BB, Miller TR, Carr TL, Cassar S, Sharma R, Faghih R, Surber BW, Esbenshade TA, Hancock AA, Krueger KM.

Br J Pharmacol. 2006 Jul;148(5):657-70. Epub 2006 May 22.

17.

Differences in pharmacological properties of histamine H(3) receptor agonists and antagonists revealed at two human H (3) receptor isoforms.

Esbenshade TA, Krueger KM, Yao BB, Witte DG, Estvander BR, Baranowski JL, Miller TR, Hancock AA.

Inflamm Res. 2006 Apr;55 Suppl 1:S45-6. No abstract available.

PMID:
16705378
18.

Distinctions and contradistinctions between antiobesity histamine H(3) receptor (H (3)R) antagonists compared to cognition-enhancing H (3) receptor antagonists.

Hancock AA, Bitner RS, Krueger KM, Otte S, Nikkel AL, Fey TA, Bush EN, Dickinson RW, Shapiro R, Knourek-Segel V, Droz BA, Brune ME, Jacobson PB, Cowart MD, Esbenshade TA.

Inflamm Res. 2006 Apr;55 Suppl 1:S42-4. No abstract available.

PMID:
16547814
19.

The use of heat transfer fluids in the synthesis of high-quality CdSe quantum dots, core/shell quantum dots, and quantum rods.

Asokan S, Krueger KM, Alkhawaldeh A, Carreon AR, Mu Z, Colvin VL, Mantzaris NV, Wong MS.

Nanotechnology. 2005 Oct;16(10):2000-11. doi: 10.1088/0957-4484/16/10/004. Epub 2005 Aug 3.

PMID:
20817962
20.

Use of novel, non-imidazole inverse agonist radioligands to define histamine H3 receptor pharmacology.

Esbenshade TA, Yao BB, Witte DG, Carr TL, Sharma R, Baranowski JL, Krueger KM, Miller TR, Surber BW, Faghih R, Hancock AA.

Inflamm Res. 2005 Apr;54 Suppl 1:S46-7. No abstract available.

PMID:
15928830
21.

Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.

Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB.

Inflamm Res. 2005 Apr;54 Suppl 1:S27-9. No abstract available.

PMID:
15928821
22.

Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia.

Fox GB, Esbenshade TA, Pan JB, Browman KE, Zhang M, Ballard ME, Radek RJ, Miner H, Bitner RS, Krueger KM, Yao BB, Faghih R, Rueter LE, Komater VA, Drescher KU, Buckley MJ, Sullivan JP, Cowart MD, Decker MW, Hancock AA.

Inflamm Res. 2005 Apr;54 Suppl 1:S23-4. No abstract available.

PMID:
15928819
23.

Characterization of nanocrystalline CdSe by size exclusion chromatography.

Krueger KM, Al-Somali AM, Falkner JC, Colvin VL.

Anal Chem. 2005 Jun 1;77(11):3511-5.

PMID:
15924382
24.

G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.

Krueger KM, Witte DG, Ireland-Denny L, Miller TR, Baranowski JL, Buckner S, Milicic I, Esbenshade TA, Hancock AA.

J Pharmacol Exp Ther. 2005 Jul;314(1):271-81. Epub 2005 Apr 8.

PMID:
15821027
25.

Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.

Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA.

J Pharmacol Exp Ther. 2005 Apr;313(1):165-75. Epub 2004 Dec 17.

PMID:
15608078
26.

Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.

Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA.

J Pharmacol Exp Ther. 2005 Apr;313(1):176-90. Epub 2004 Dec 17.

PMID:
15608077
27.

Recycling size exclusion chromatography for the analysis and separation of nanocrystalline gold.

Al-Somali AM, Krueger KM, Falkner JC, Colvin VL.

Anal Chem. 2004 Oct 1;76(19):5903-10.

PMID:
15456313
28.

In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.

Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB.

Basic Clin Pharmacol Toxicol. 2004 Sep;95(3):144-52.

29.

Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.

Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA.

Biochem Pharmacol. 2004 Sep 1;68(5):933-45.

PMID:
15294456
30.

D-amino acid homopiperazine amides: discovery of A-320436, a potent and selective non-imidazole histamine H(3)-receptor antagonist.

Curtis MP, Dwight W, Pratt J, Cowart M, Esbenshade TA, Krueger KM, Fox GB, Pan JB, Pagano TG, Hancock AA, Faghih R, Bennani YL.

Arch Pharm (Weinheim). 2004 Apr;337(4):219-29.

PMID:
15146898
31.

Structure-activity relationships of A-331440: a new histamine-3 antagonist with anti-obesity properties.

Faghih R, Esbenshade TA, Krueger KM, Yao BB, Witte DG, Miller TM, Kang CH, Fox GB, Cowart M, Bennani YL, Hancock AA.

Inflamm Res. 2004 Mar;53 Suppl 1:S79-80. Epub 2004 Mar 5. No abstract available.

PMID:
15054629
32.

Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.

Hancock AA, Bennani YL, Bush EN, Esbenshade TA, Faghih R, Fox GB, Jacobson P, Knourek-Segel V, Krueger KM, Nuss ME, Pan JB, Shapiro R, Witte DG, Yao BB.

Eur J Pharmacol. 2004 Mar 8;487(1-3):183-97.

PMID:
15033391
33.

Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists.

Gfesser GA, Zhang H, Dinges J, Fox GB, Pan JB, Esbenshade TA, Yao BB, Witte D, Miller TR, Kang CH, Krueger KM, Bennani YL, Hancock AA, Faghih R.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):673-6.

PMID:
14741266
34.

Genetic and pharmacological aspects of histamine H3 receptor heterogeneity.

Hancock AA, Esbenshade TA, Krueger KM, Yao BB.

Life Sci. 2003 Oct 31;73(24):3043-72. Review.

PMID:
14550847
35.

D-alanine piperazine-amides: novel non-imidazole antagonists of the histamine H3 receptor.

Faghih R, Phelan K, Esbenshade TA, Miller TR, Kang CH, Krueger KM, Yao BB, Fox GB, Bennani YL, Hancock AA.

Inflamm Res. 2003 Apr;52 Suppl 1:S47-8. No abstract available.

PMID:
12755406
36.

In vitro pharmacological properties of two novel non-imidazole H3 receptor (H3R) antagonists.

Yao BB, Witte DG, Miller TR, Krueger KM, Carr TL, Kang CH, Faghih R, Bennani YL, Esbenshade TA, Hancock AA.

Inflamm Res. 2003 Apr;52 Suppl 1:S45-6. No abstract available.

PMID:
12755405
37.

Differential activation of dual signaling responses by human H1 and H2 histamine receptors.

Esbenshade TA, Kang CH, Krueger KM, Miller TR, Witte DG, Roch JM, Masters JN, Hancock AA.

J Recept Signal Transduct Res. 2003 Feb;23(1):17-31.

PMID:
12680587
38.

Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists.

Faghih R, Dwight W, Pan JB, Fox GB, Krueger KM, Esbenshade TA, McVey JM, Marsh K, Bennani YL, Hancock AA.

Bioorg Med Chem Lett. 2003 Apr 7;13(7):1325-8.

PMID:
12657274
39.

Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.

Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, Williams M, Hancock AA.

J Pharmacol Exp Ther. 2003 Jun;305(3):887-96. Epub 2003 Feb 20.

PMID:
12606603
40.

Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.

Faghih R, Dwight W, Black L, Liu H, Gentles R, Phelan K, Esbenshade TA, Ireland L, Miller TR, Kang CH, Krueger KM, Fox GB, Hancock AA, Bennani YL.

Bioorg Med Chem Lett. 2002 Aug 5;12(15):2035-7.

PMID:
12113836
41.

Species-related pharmacological heterogeneity of histamine H(3) receptors.

Ireland-Denny L, Parihar AS, Miller TR, Kang CH, Krueger KM, Esbenshade TA, Hancock AA.

Eur J Pharmacol. 2001 Dec 21;433(2-3):141-50.

PMID:
11755145
42.

Clathrin-mediated endocytosis of the beta-adrenergic receptor is regulated by phosphorylation/dephosphorylation of beta-arrestin1.

Lin FT, Krueger KM, Kendall HE, Daaka Y, Fredericks ZL, Pitcher JA, Lefkowitz RJ.

J Biol Chem. 1997 Dec 5;272(49):31051-7.

44.

G-protein-coupled receptors and their regulation: activation of the MAP kinase signaling pathway by G-protein-coupled receptors.

Luttrell LM, van Biesen T, Hawes BE, Koch WJ, Krueger KM, Touhara K, Lefkowitz RJ.

Adv Second Messenger Phosphoprotein Res. 1997;31:263-77. Review.

PMID:
9344257
45.

Receptor-tyrosine-kinase- and G beta gamma-mediated MAP kinase activation by a common signalling pathway.

van Biesen T, Hawes BE, Luttrell DK, Krueger KM, Touhara K, Porfiri E, Sakaue M, Luttrell LM, Lefkowitz RJ.

Nature. 1995 Aug 31;376(6543):781-4.

PMID:
7651538
46.

The family of bacterial ADP-ribosylating exotoxins.

Krueger KM, Barbieri JT.

Clin Microbiol Rev. 1995 Jan;8(1):34-47. Review.

48.

Molecular characterization of the in vitro activation of pertussis toxin by ATP.

Krueger KM, Barbieri JT.

J Biol Chem. 1993 Jun 15;268(17):12570-8.

49.

Effect of selegiline on speech performance in Parkinson's disease.

Shea BR, Drummond SS, Metzer WS, Krueger KM.

Folia Phoniatr (Basel). 1993;45(1):40-6.

PMID:
8482574
50.

The carboxyl terminus of the S1 subunit of pertussis toxin confers high affinity binding to transducin.

Cortina G, Krueger KM, Barbieri JT.

J Biol Chem. 1991 Dec 15;266(35):23810-4.

Supplemental Content

Loading ...
Support Center